By Ankit Gohel Jan 9, 2020 8:06:33 AM IST (Updated)
The inspection was carried out from January 6 to January 8, 2020 and was completed successfully without any observations.
Alembic Pharmaceuticals Ltd. said that its joint venture firm Aleor Dermaceuticals has completed the United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility at Karakhadi without any observations.
Recommended Articles
View All
India’s foreign trade policy aims to make rupee stronger — here’s how it may work
Mar 31, 2023 IST5 Min(s) Read
IT increments this year will be the lowest in a decade — sans 2020, finds survey
Mar 31, 2023 IST3 Min(s) Read
Data Security in BFSI: How to strengthen cybersecurity in the financial services industry
Mar 31, 2023 IST5 Min(s) Read
Protection against flu — we must act now to help strengthen India’s prevention strategy
Mar 31, 2023 IST3 Min(s) Read
In a regulatory filing on Wednesday, the company said that the inspection was carried out from January 6 to January 8, 2020 and was completed successfully without any observations.
Aleor Dermaceuticals is a 60:40 Joint Venture (JV) between Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies, it added.
First Published: Jan 9, 2020 8:03 AM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
